# US 2025/0375373 A1 · Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375373 A1
- Document ID: US20250375373A1
- Status: Published application
- Kind: A1
- Application number: 19/261,767
- Filed: 2025-07-07
- Published: 2025-12-11
- Earliest claimed: 2018-05-09
- Assignees: Azurity Pharmaceuticals, Inc.
- Applicants: Azurity Pharmaceuticals, Inc.
- Inventors: Rahul Dhulaji BHISE; Ajay Kumar SINGH; Mahadeo Vasant MAHADIK; Ashish Anilrao DUBEWAR; Molugu Prashanth REDDY
- Web page: https://patentgrep.com/patent/US20250375373A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

## Claims

### Claim 1

A ready-to-use injectable pharmaceutical composition comprising:
(i) neostigmine or a pharmaceutically acceptable salt, solvate or hydrate thereof;
(ii) glycopyrrolate or a pharmaceutically acceptable salt, solvate or hydrate thereof; and
(iii) a pharmaceutically acceptable liquid vehicle,
wherein a level of Glycopyrrolate Impurity C in the composition is less than 1% when stored at 40° C. and 75% relative humidity for at least 3 months.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, comprising neostigmine methylsulfate and glycopyrronium bromide.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition is provided in a sealed container selected from a vial or a pre-filled syringe.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition is provided in a clear glass vial, an amber glass vial, a plastic vial or a pre-filled syringe.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition is in the form of a solution.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition is suitable for subcutaneous, intravenous or intramuscular administration.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition has a pH from about 3.0 to about 4.0.

### Claim 8 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition has a pH from about 3.0 to about 3.5.

### Claim 9 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition has a pH from about 2.0 to about 5.0.

### Claim 10 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising a tonicity modifier.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the tonicity modifier comprises glycerine, lactose, mannitol, dextrose, sodium chloride, sodium sulphate, sorbitol, trehalose, or combinations thereof.

### Claim 12 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the tonicity modifier is present in a concentration from about 1 mg/mL to about 20 mg/ml of the composition.

### Claim 13 (depends on 10)

The pharmaceutical composition according to claim 10, wherein the tonicity modifier is present in a concentration from about 5 mg/mL to about 10 mg/mL.

### Claim 14 (depends on 1)

The pharmaceutical composition according to claim 1, which is stable for at least 3 months at 25° C. and 60% relative humidity.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein the level of Glycopyrrolate Impurity C is less than 1% (w/w) as measured by HPLC.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is sterilized.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is sterilized using filtration through a bacterial-retaining filter, terminal sterilization, incorporation of sterilizing agents, irradiation, heating, or combinations thereof.

### Claim 18 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is sterilized using aseptic filling, irradiation, heat sterilization or combinations thereof.

### Claim 19 (depends on 1)

The pharmaceutical composition according to claim 1, comprising neostigmine methylsulfate or a pharmaceutically acceptable salt, solvate or hydrate at a concentration of about 0.5 mg/mL.

### Claim 20 (depends on 1)

The pharmaceutical composition according to claim 1, comprising neostigmine methylsulfate or a pharmaceutically acceptable salt, solvate or hydrate at a concentration of about 2.5 mg/mL.

### Claim 21 (depends on 1)

The pharmaceutical composition according to claim 1, comprising glycopyrrolate or a pharmaceutically acceptable salt, solvate or hydrate thereof at a concentration of about 0.1 mg/mL.

### Claim 22 (depends on 1)

The pharmaceutical composition according to claim 1, comprising glycopyrrolate or a pharmaceutically acceptable salt, solvate or hydrate thereof at a concentration of about 0.5 mg/mL.

### Claim 23 (depends on 1)

A method for treating a neuromuscular disease, comprising administering the pharmaceutical composition according to claim 1 to a patient in need thereof.
